Maze Therapeutics is a pre-profitability biotechnology company whose entire commercial thesis depends on a single pipeline asset (MZE829), with free cash flow deeply negative at roughly 409% of revenue and a quality profile below minimum investment thresholds. The 124% upside implied by the analyst consensus price target and an 11-to-1 favorable risk/reward ratio reflect binary clinical optionality, while an exceptionally elevated put/call ratio of 13.00 signals that sophisticated options participants are positioned for significant near-term downside.
Thesis pillars
- Single Asset Pipeline Concentration↓Deteriorating
- Large Analyst Upside Optionality↓Deteriorating
- Severe Cash Burn Rate→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 25, 2026· older than 90 days
Maze Therapeutics, Inc. (MAZE) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.38: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 3.33; Below-average business quality.
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with no approved products or product revenue. Lead program MZE829 (APOL1 inhibitor, Phase 2 for AMKD) delivered positive... Read more
Sell if holding. Engine safety override at $33.38: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 3.33; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 74. Score 5.4/10, moderate confidence.
Passes 5/9 gates (positive momentum, favorable risk/reward ratio, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
About Maze Therapeutics, Inc.
About Maze Therapeutics, Inc.
Maze Therapeutics' lead program MZE829, an oral APOL1 inhibitor for APOL1-mediated kidney disease (AMKD), delivered positive Phase 2 topline data in March 2026, showing a mean 35.6% urinary albumin-to-creatinine ratio reduction at week 12 in evaluable patients. The company recorded no product revenue and a net loss of $131.1 million in fiscal year 2025, holding $360.0 million in cash and marketable securities at December 31, 2025. A second program, MZE782, completed Phase 1 for phenylketonuria (PKU) and CKD in September 2025.
Maze Therapeutics finances operations through equity offerings, convertible notes, debt, and nonrefundable licensing payments, having generated no product revenue since inception. In February 2026, the company entered a senior secured term loan with Hercules Capital for up to $200.0 million, with $40.0 million funded at closing; additional tranches are available through February 2031 at Prime Rate-referenced rates with floors of 7.95% to 9.25% depending on the tranche. MZE829 targets AMKD—a genetically driven CKD subtype affecting an estimated 250,000 addressable U.S. patients carrying two high-risk APOL1 variants—with no approved therapy currently available. MZE782 targets PKU and CKD, with two Phase 2 trials planned for 2026. A third program, MZE001 (S606001), was licensed to Shionogi & Co., Ltd. and is in Phase 2 development for Pompe disease.
Show full overview
Maze's enterprise value rests almost entirely on MZE829's pivotal development path: the completed Phase 2 trial enrolled only 15 patients, and a larger registrational trial must demonstrate safety and efficacy sufficient for FDA marketing approval. The Hercules Loan Agreement imposes a covenant requiring Maze to maintain unrestricted cash above 50% of outstanding principal unless market capitalization exceeds $450.0 million—a constraint that links clinical execution risk directly to refinancing capacity. Any material trial delay or FDA request for additional studies could deplete cash reserves and accelerate covenant pressure before the company reaches a commercial milestone.
See also: Healthcare · Biotechnology
From Maze Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Maze Therapeutics, Inc.
Latest news
- NEWS Maze Therapeutics Announces Participation in Upcoming Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS Canaccord Genuity Initiates Coverage of Maze Therapeutics with Buy Rating — fiscal.ai Oct 19, 2026 positive
- NEWS Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75 — benzinga Oct 19, 2026 positive
- NEWS Maze Therapeutics Announces Presentation Of Updated Phase 2 MZE829 Kidney Disease Data At ASN Kidney Week On October 24 — benzinga Oct 6, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target — benzinga Sep 24, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-05T11:54:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineMZE82910-K Item 1A: 'highly dependent on the success of our lead programs ... MZE829, our most advanced lead program'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWNeil Kumar appointed as Class I director effective March 27, 2026. Kumar is co-founder and CEO of BridgeBio Pharma, Inc. Routine board appointment; no departure involved.SEC filing →
- 2026-05-22Item 5.02LOWAmy Bachrodt, SVP Finance, resigned effective June 1, 2026. CFO Misbah Tahir designated as principal accounting officer upon her departure. No disagreement with company operations or financial reporting cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.38: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 3.33; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 74. Prior stop was $31.04. Score 5.4/10, moderate confidence.
Analyst target: $54.41 (+63.0% upside). Prior stop was $31.04. Stop-loss: $31.04.
Concentration risk — Pipeline: MZE829; Quality below floor (3.4 < 4.0).
Maze Therapeutics, Inc. trades at a P/E of N/A (forward -10.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts rate MAZE, with a consensus score of 4.3/5. 13 analysts publish price targets averaging $63.
What does Maze Therapeutics, Inc. do?Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for...
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with no approved products or product revenue. Lead program MZE829 (APOL1 inhibitor, Phase 2 for AMKD) delivered positive proof-of-concept data in March 2026; second program MZE782 completed Phase 1 for PKU and CKD in September 2025. The company held $360.0 million in cash at year-end 2025 and had accumulated a deficit of $489.5 million.